Clinical UpdatesClostridioides difficilemicrobiome therapeutics
Precision Microbiome Therapeutics: Faecalibacterium prausnitzii EXL01 for Prevention of Multiple-Recurrent Clostridioides difficile Infection
By MedXY|Sep 21, 2026
Faecalibacterium prausnitzii EXL01, a single commensal bacterial strain, shows promise in preventing multiple-recurrent CDI by restoring key microbiome functions, including bile acid metabolism and butyrate production, with safety and effic